arrow
A

Andrew Pink

king's college london
H指数:31
被引数:4,456

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Set targets, assess response, intervene early to achieve minimal disease activity in atopic dermatitis (STRIVE AD): A modified Delphi consensus project to optimize management of atopic dermatitis in the United Kingdom

设定目标、评估反应、早期干预以实现特应性皮炎的最小疾病活动度(STRIVE AD):一项优化英国特应性皮炎管理的改良德尔菲共识项目

2026-01-010
OAAI
Single-cell multiomic atlas of systemic treatment action in atopic eczema

特应性湿疹系统性治疗作用的单细胞多组学图谱

2026-01-010
PRE
Development of a PsA-like presentation under anti-IL-13 therapy with tralokinumab for atopic dermatitis

使用特拉斯库单抗治疗特应性皮炎期间出现银屑病关节炎样表现的发展

2025-12-010
PRE
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

奈莫珠单抗治疗结节性痒疹长达100周: 奥林匹亚LTE中期分析

2025-12-010
OAAI
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

罗卡替利单抗治疗中重度特应性皮炎的疗效与安全性:ROCKET-IGNITE和ROCKET-HORIZON两项全球性、双盲、安慰剂对照、随机III期临床研究

2025-11-250
PRE
Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of eight clinical trials

特应性皮炎患者中特立洛金单抗的安全性(随访长达4.5年):一项八项临床试验的整合分析

2025-11-011
OAAI
Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)

通过乌帕替尼实现中重度特应性皮炎的最佳治疗目标和最低疾病活动度:第3期研究(Measure Up 1和2)的综合分析

2025-07-140
OA
Impact of amlitelimab (an anti-OX40 ligand antibody) on atopic dermatitis by body region: post hoc results from the STREAM-AD phase IIb study of moderate-to-severe atopic dermatitis

阿利替莫单抗(一种抗OX40配体抗体)对按身体区域划分的特应性皮炎的影响:来自中重度特应性皮炎STREAM-AD IIb期研究的回顾性结果

2025-07-010
OAAI
A novel self-referral enrolment pathway in a UK multicentre atopic dermatitis trial (BEACON trial): a single-site prospective observational study to assess feasibility and effectiveness

一项在英国多中心特应性皮炎试验(BEACON试验)中的新型自推荐入组路径:一项单中心前瞻性观察性研究,旨在评估可行性与有效性

2025-07-010
OA
Harnessing artificial intelligence-based image analysis and self-reported data for the assessment of psoriasis severity

利用基于人工智能的图像分析和自报数据对银屑病严重程度进行评估

2025-07-010
OAAI
Response to Lavin et al (2025)’s Paper: Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System

对Lavin et al (2025)论文的回应:使用Dupilumab后的皮肤T细胞淋巴瘤:一项基于FDA不良事件报告系统的真实世界药物警戒研究

2025-06-300
PRE